| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The strategic collaboration will leverage Tempus' large multimodal datasets to enhance BioNTech's next-generation oncology pipeline
Tempus AI, Inc. (NASDAQ:TEM, "Tempus"))))), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX, "BioNTech"))))), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech's next-generation oncology pipeline.
Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline. BioNTech will work collaboratively with Tempus to leverage Tempus' real-world multimodal database to generate novel insights into the biological mechanisms supporting the discovery of new therapies and aiming to enhance the development of BioNTech's clinical oncology pipeline.
